ESMO

Addition of PARP Inhibitor to Maintenance Therapy May Improve Survival in Ovarian Cancer

September 28th 2019, 11:18pm

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Erleada May Extend Subsequent Progression in Men With Castration-Resistant Prostate Cancer

September 28th 2019, 6:43pm

Article

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

Latest News

Challenging Assumptions About Cancer and Its Treatments

Sharing Stories of Survivorship

Perioperative Therapy in Resectable NSCLC: The Drive for a Cure

How My Daughter Stood Up to Breast Cancer

View More Latest News